Zydus Lifesciences scored a major landmark earlier this year when it scooped the first US Food and Drug Administration approval for a generic version of AstraZeneca’s Farxiga (dapagliflozin), “the fastest growing SGLT2 inhibitor globally.”
Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued
ANDA Sponsor And AstraZeneca Disagreed On Chances Of Settlement
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.
More from Generics
• By
The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.
• By
Sunshine Biopharma is continuing to roll out generic launches in Canada, with its latest product challenging Afinitor and other everolimus rivals in the market.
• By
Generics Bulletin reviews global regulatory developments across the world.
• By
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.
More from Products
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
• By
In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.
• By
Generics Bulletin reviews global regulatory developments across the world.